ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2017, …

A phase 3 pivotal trial – PANOVA-3 – will test the efficacy of TTFields with gemcitabine and nab-paclitaxel as a front-line treatment of locally advanced pancreatic cancer ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the company will present three abstracts studying Tumor Treating Fields (TTFields) in pancreatic cancer at the European Society …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that the time of its presentation at the JMP Securities 2017 Life Sciences Conference has changed. The presentation at the conference is now scheduled for 10:30 am EDT on June 21, 2017, in New York. A live audio webcast of the presentation can be accessed from the …

The RTOG 3503 phase 2 pilot trial is the first consortium study to test treatment with Optune ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure™ (NASDAQ: NVCR) announced today that the first patient has been enrolled in the RTOG Foundation’s phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM). Optune is …

More than 204 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that Health Care Service Corporation (HCSC) will cover Optune for members who have newly diagnosed glioblastoma (GBM) effective June 15, 2017. HCSC is the largest customer-owned health insurer …

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that it will participate in the JMP Securities 2017 Life Sciences Conference on June 21, 2017, in New York. Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, will speak on behalf of the company and address questions from analysts. Dr. Kirson’s presentation …